Circulating Fetal Cell (CFC) Capture and Isolation

Isolation of circulating fetal cells (CFCs) from maternal peripheral blood has been a major goal for non-invasive prenatal diagnosis. Up until now, engineering difficulty and ineffective bioreagent and system integration have resulted in inconsistent fetal cell capturing and purity, hampering its long-sought prenatal application and deployment in the commercial setting. Abnova develops and provides GMP bioreagent and system solutions for isolation of CFCs as early as 7 week of gestation, thereby providing access to the complete fetal nuclear genome for genetic analysis via fluorescent in situ hybridization (FISH), microarray, and next generation sequencing (NGS).

CytoQuest™ CR - Circulating Fetal Cell Capture and Isolation

Prenatal Testing vs. Diagnosis

	Amniocentesis	Chorionic Villus Sampling (CVS)	Cell-free DNA	Circulating Fetal Cell
Sample	Fetal Cells	Placental Tissues	Mixtures of Fetal and Maternal DNA	Fetal Cells
Coverage	High	High	Low T13, T18, T21 & Sex	High
Accuracy	High	High	High for T21	High
Timing	16 weeks	10 weeks	>9 weeks	>7 weeks
Invasive	Yes	Yes	No	No
Risks to Fetus	Yes	Yes	No	No
Testing vs. Diagnosis	Diagnosis	Diagnosis	Testing	Diagnosis

CytoQuest™ CR system, SCx™ spiral chamber, HBx™ micromixer, and TCx™ thermal control are trademarks and pending patents of Abnova Corporation.